

To: [redacted]@rivm.nl; [redacted]@rivm.nl
Cc: [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl; [redacted]@rivm.nl;
From: [redacted]
Sent: Wed 1/13/2021 11:53:12 AM
Subject: SARS-CoV-2 variants; webex morgen
Received: Wed 1/13/2021 11:53:13 AM

Beste [redacted]

Er zijn gisteren verzoeken binnengekomen uit verschillende landen. Naast [redacted] zien we ook verzoeken [redacted]

We weten nu niet precies welk verzoek je binnen hebt gekregen en of het handig is om morgen ook direct [redacted] en [redacted] uit te nodigen. Het gaat allemaal over de diverse covid varianten (UK en SA variant) dus mij lijkt het handig om deze landen ook meteen toe te voegen aan het overleg.

Ben je het hiermee eens of wil je het beperken tot [redacted]

Groeten,

[redacted]

From: [redacted]
Sent: Tuesday, 12 January 2021 19:48
To: [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]
Cc: [redacted]; [redacted]
Subject: Re: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Hoi,

[redacted] weet ervan en probeert voor donderdagmiddag een Webex te laten organiseren met o.a. hoofden RKI en AU. Ik overleg even met hem wie er vanuit IDS kan aansluiten.

Groet,

[redacted]

From: [redacted]
Sent: Tuesday, 12 January 2021 19:28:58
To: [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]
Cc: [redacted]; [redacted]
Subject: Re: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Hoi,

Hoor Rutte het net ook noemen in de persconferentie. Heb het ook even in de app gevraagd aan [redacted] laat het weten als ik daar wat van hoor.

Groet.

[redacted]

From: [redacted]; [redacted]

Sent: Tuesday, 12 January 2021 17:55:10

To: [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]; [redacted]

Cc: [redacted]; [redacted]

Subject: RE: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Ha,

Heel graag want ik weet niet wat er afgesproken is en dit vandaan komt.

Gr [redacted]

Van: [redacted] [redacted] <[redacted]@rivm.nl>

Datum: 12 januari 2021 om 15:43:38 CET

Aan: [redacted] [redacted] <[redacted]@rivm.nl>, [redacted] [redacted] <[redacted]@rivm.nl>, [redacted] [redacted] [redacted] <[redacted]@rivm.nl>, [redacted] [redacted] [redacted] <[redacted]@rivm.nl>

CC: [redacted] [redacted] <[redacted]@rivm.nl>

Onderwerp: RE: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Hoi [redacted]

Ik heb nagevraagd maar dit is bij ons (BDR internationaal) niet bekend.

We hebben geen 'formele' samenwerking met RKI en SSI, natuurlijk wel contact via IANPHI en IC4Health en via de nodige internationale projecten.

Er is hierover voor zover we weten ook nog niets vanuit Den Haag tot ons gekomen. Gezien het over sequencing van de covid variant gaat lijkt het me logisch als de inhoudelijke component bij IDS/CIB ligt.

Wil je dat ik dit navraag bij onze collega's van VWS-IZ?

Vriendelijke groeten,

[redacted]

-----Original Message-----

From: [redacted] [redacted] <[redacted]@rivm.nl>

Sent: dinsdag 12 januari 2021 10:30

To: [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@rivm.nl>

<[redacted]@rivm.nl>

Subject: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Hoi,

Weet één van jullie hiervan?

Hoe komen we hier achter (als jullie van niets weten 💎).

Groet [redacted]

-----Original Message-----

From: [redacted] [redacted] <[redacted]@rki.de>

Sent: dinsdag 12 januari 2021 10:17

To: [redacted] [redacted] <[redacted]@rivm.nl>; [redacted] [redacted] ([redacted]@ssi.dk) <[redacted]@ssi.dk>

Cc: Secretariaat CIB <[redacted]@rivm.nl>; [redacted] [redacted] <[redacted]@rki.de>

Subject: SARS-CoV-2 variants; Interaction NL-Dk-De on federal level

Dear [redacted] dear [redacted]

the current one is an amazing time. I learned yesterday from our Institute's head that the [redacted] chancellor recently agreed with the Dutch and [redacted] heads of governments in following up on SARS-CoV-2 variants in a collaboration between the National Public Health institutes, e.g. RIVM, SSI and RKI. On our end we are expected to initially report on this to the Government by tonite (!) I am wondering whether you have any information from side of your institutes on this, who would be in charge as a contact, and whether there are any particular plans/ideas? Given the spread and dynamics of SARS-CoV-2 variants from UK, ZA, BRA with potentially increased transmission and/or reduced antibody reactivity in European countries, and the heterogenous levels of their follow-up, it certainly makes sense to look on that on a supranational level.

Both UK and SA variants have been detected in several places in the meantime in Germany, unsurprisingly. In response to this variant scare, there are some immediate reactions, which includes scaling up sequencing of genomes at our institute and financial compensations to laboratories for submitting genome sequences (soon to be released). We will submit every variant result to GISAID and are currently trying to grow virus from samples. Clearly, vaccine coverage of variant viruses and the methodology involved will become an important issue here.

Could you please let me know as soon as possible, whether you are aware of this in your institutes and who would possibly be authorized to discuss initial topics/ideas?

I apologize for this rush and look forward to your responses. You can also contact me today directly at my mobile at

5.1.2e

Best regards,

5.1.2e

5.1.2e

Robert Koch-Institut
Head, Unit 17, Influenza and other Respiratory Viruses Seestr. 10
13353 Berlin
Germany
Tel.: +
Fax.: + 5.1.2e
E-mail: 5.1.2e@RKI.de

The Robert Koch-Institute is a Federal Institute within the portfolio of the Federal Ministry of Health.